Cleerly and Cardiac Care Alliance have entered into a strategic partnership to offer Cleerly's AI-enabled coronary artery disease assessment technology to payers and practices in Cardiac Care Alliance's network.
Under the collaboration, Cleerly's Artificial Intelligence-Quantitative Coronary Tomography (AI-QCT) technology will be used to assess symptomatic patients in Cardiac Care Alliance's cardiovascular care network prior to cardiac catheterization procedures. The initiative will launch initially with cardiology practices in Texas, with plans for broader implementation, according to Cleerly.
AI-QCT is designed to provide noninvasive assessment of atherosclerosis (plaque), stenosis, and likelihood of ischemia based on cardiac CT angiography.
